RAI2 and pachyonychia congenita: Notably, while RAI2 gene expression was detected in 89% of CTC-positive blood samples in CRPC patients, this rate decreased to 35% in AVPC and 19% in NEPC patients (Fig. 5b), suggesting that loss of RAI2 to be associated with PC progression to treatment-resistant disease stages.